<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<META NAME="ROBOTS" CONTENT="NOINDEX, NOFOLLOW, NOARCHIVE">
<meta name=Generator content="Microsoft Office HTML Filter 2.0">

<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Originator content="Microsoft Word 9">
<title>Apotex Inc. v. Hoffman La-Roche Limited (December 14, 2000)</title>
<style>
<!--
 
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{
	margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
h1
	{
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	page-break-after:avoid;
	font-size:15.0pt;
	font-family:"Times New Roman";
	font-weight:normal;}
h2
	{
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	page-break-after:avoid;
	font-size:15.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
h3
	{
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:Arial;
	font-weight:bold;}
h4
	{
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
h5
	{
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	font-size:13.0pt;
	font-family:"Times New Roman";
	font-weight:bold;
	font-style:italic;}
h6
	{
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	font-size:11.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	font-size:12.0pt;
	font-family:"Times New Roman";}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	font-size:11.0pt;
	font-family:Arial;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:10.0pt;
	margin-bottom:.0001pt;
	text-indent:-10.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:20.0pt;
	margin-bottom:.0001pt;
	text-indent:-10.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:30.0pt;
	margin-bottom:.0001pt;
	text-indent:-10.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:40.0pt;
	margin-bottom:.0001pt;
	text-indent:-10.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:50.0pt;
	margin-bottom:.0001pt;
	text-indent:-10.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:60.0pt;
	margin-bottom:.0001pt;
	text-indent:-10.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:70.0pt;
	margin-bottom:.0001pt;
	text-indent:-10.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:80.0pt;
	margin-bottom:.0001pt;
	text-indent:-10.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:90.0pt;
	margin-bottom:.0001pt;
	text-indent:-10.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{
	margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:10.0pt;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:20.0pt;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:30.0pt;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:40.0pt;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:50.0pt;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:60.0pt;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:70.0pt;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:80.0pt;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{
	margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:Arial;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{
	margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:20.0pt;
	margin-bottom:.0001pt;
	text-indent:-20.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:144.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:Arial;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:Arial;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoToa, li.MsoToa, div.MsoToa
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:10.0pt;
	margin-bottom:.0001pt;
	text-indent:-10.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{
	margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{
	margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:Arial;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	text-indent:-14.15pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:18.0pt;
	margin-bottom:.0001pt;
	text-indent:-18.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:18.0pt;
	margin-bottom:.0001pt;
	text-indent:-18.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	text-indent:-14.15pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	text-indent:-14.15pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	text-indent:-14.15pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	text-indent:-14.15pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:32.15pt;
	margin-bottom:.0001pt;
	text-indent:-18.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:46.3pt;
	margin-bottom:.0001pt;
	text-indent:-18.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:60.45pt;
	margin-bottom:.0001pt;
	text-indent:-18.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:74.6pt;
	margin-bottom:.0001pt;
	text-indent:-18.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:32.15pt;
	margin-bottom:.0001pt;
	text-indent:-18.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:46.3pt;
	margin-bottom:.0001pt;
	text-indent:-18.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:60.45pt;
	margin-bottom:.0001pt;
	text-indent:-18.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:74.6pt;
	margin-bottom:.0001pt;
	text-indent:-18.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	text-align:center;
	font-size:16.0pt;
	font-family:Arial;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:212.6pt;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:212.6pt;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:2.0cm;
	margin-bottom:.0001pt;
	text-indent:-2.0cm;
	background:#CCCCCC;
	border:none;
	padding:0cm;
	font-size:12.0pt;
	font-family:Arial;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	text-align:center;
	font-size:12.0pt;
	font-family:Arial;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{
	margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoDate, li.MsoDate, div.MsoDate
	{
	margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	text-indent:10.5pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{
	margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	line-height:200%;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	font-size:8.0pt;
	font-family:"Times New Roman";}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:200%;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:8.0pt;
	font-family:"Times New Roman";}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0cm;
	margin-right:72.0pt;
	margin-bottom:6.0pt;
	margin-left:72.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0cm;
	margin-bottom:.0001pt;
	background:navy;
	font-size:10.0pt;
	font-family:Tahoma;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman";}
address
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-style:italic;}
pre
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.headingtitle, li.headingtitle, div.headingtitle
	{
	margin-top:18.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.headingNUMBER, li.headingNUMBER, div.headingNUMBER
	{
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	text-align:justify;
	text-indent:0cm;
	line-height:200%;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.headingsubtitle, li.headingsubtitle, div.headingsubtitle
	{
	margin-top:18.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:36.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.headingsubsubtitle, li.headingsubsubtitle, div.headingsubsubtitle
	{
	margin-top:18.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:72.0pt;
	margin-bottom:.0001pt;
	text-indent:0cm;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.headingQUOTE, li.headingQUOTE, div.headingQUOTE
	{
	margin-top:6.0pt;
	margin-right:72.0pt;
	margin-bottom:12.0pt;
	margin-left:72.0pt;
	text-align:justify;
	text-indent:0cm;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.headingblank, li.headingblank, div.headingblank
	{
	margin-top:18.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	margin-bottom:.0001pt;
	text-indent:0cm;
	line-height:200%;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.heading3subtitle, li.heading3subtitle, div.heading3subtitle
	{
	margin-top:18.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:72.0pt;
	margin-bottom:.0001pt;
	text-indent:-36.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman";}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
</head>

<body lang=EN-CA>

<div class=Section1>

<p class=MsoNormal align=right style='text-align:right'><span lang=EN-US
style='font-size:13.0pt;'>DATE:   20001214</span></p>

<p class=MsoNormal align=right style='text-align:right'><span lang=EN-US
style='font-size:13.0pt;'>DOCKET: C33172</span></p>

<p class=MsoNormal align=right style='text-align:right'><span lang=EN-US
style='font-size:13.0pt;'>&nbsp;</span></p>

<h1><b><span lang=EN-US>COURT OF APPEAL FOR
ONTARIO</span></b></h1>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-US
style='font-size:15.0pt;'>&nbsp;</span></p>

<h2><span lang=EN-US>McMURTRY C.J.O., MORDEN and ROSENBERG JJ.A.</span></h2>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-US
style='font-size:15.0pt;'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>BETWEEN:                                               )</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>                                                                           )     Ronald G. Slaght, Q.C. and</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>APOTEX INC.                                                  )     Timothy H. Gilbert,</span></b></p>

<p class=MsoNormal><span lang=EN-US
style='font-size:12.0pt;'>                                                                           <b>)     for
the appellant</b></span></p>

<p class=MsoNormal><span lang=EN-US
style='font-size:12.0pt;'>                                                <b>Plaintiff/</b>             <b>)</b></span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>                                                Appellant           )     William
Vanveen, for the respondent</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>                                                                           )     Hoffmann La-Roche Limited</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>- and -                                                                 )     </span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>                                                                           )     J. Scott Maidment and</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>HOFFMANN LA-ROCHE LIMITED,           )     Robert Wisner,
for the respondent</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>GLAXO WELLCOME INC.,                          )     AltiMed Pharmaceutical Company Inc.</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>PHARMACIA &amp; UPJOHN INC. and             )     </span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>ALTIMED PHARMACEUTICAL                  )    Martin
Sclisizzi, for the respondent</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>COMPANY INC.                                              )     Pharmacia &amp; Upjohn Inc.</span></b></p>

<p class=MsoNormal style='margin-left:144.0pt;text-indent:36.0pt;'><span lang=EN-US style='font-size:12.0pt;'>               <b>)     </b></span></p>

<p class=MsoNormal><span lang=EN-US
style='font-size:12.0pt;'>                                                <b>Defendants/</b>       <b>)     Robert
Kwinter, for the respondent</b></span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>                                                Respondents     )     Glaxo
Wellcome Inc.</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>                                                                           )</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>                                                                           )     Heard: June 27, 2000</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>                                                                           )</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt;'>&nbsp;</span></b></p>

<p class=headingblank style='margin-left:0cm;text-indent:0cm'><span lang=EN-US>On
appeal from the order of Justice John R. Jennings dated October 22, 1999</span></p>

<p class=headingtitle><span lang=EN-US>ROSENBERG J.A.:</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[1]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>This appeal from the order of Jennings
J. striking out the plaintiff’s amended statement of claim without leave to
amend concerns principally the interpretation of the misleading advertising
provision of the <i>Competition Act</i>,
R.S.C. 1985, c. C-34.  In the amended
statement of claim, the plaintiff claims various remedies, including damages,
because of violations of various federal and provincial statutes.  Its claim is based on a civil remedy created
by the <i>Competition Act</i> and on the
torts of conspiracy and unlawful interference with economic relations.  The issue at the root of these claims is
whether the marketing strategy adopted by the defendants infringes any of these
statutes and is therefore unlawful.  For
the reasons that follow, I would allow the appeal in part.</span></p>

<p class=headingtitle><span lang=EN-US>THE FACTS</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[2]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The allegations in the amended
statement of claim may be summarized as follows.  The plaintiff company manufactures generic drug products. These
generic drug products are therapeutically equivalent, but not identical, to the
name-brand drug products that are manufactured by the name-brand defendants
Hoffman La-Roche Limited, Glaxo Wellcome Inc., and Pharmacia &amp; Upjohn Inc.
Generic drugs are generally sold after the expiry of a patent. The name-brand
defendants are holders of patents on drug products in Canada.  The defendant AltiMed was a corporation
originally incorporated and beneficially owned by the name-brand defendants to sell
the name-brand defendants’ drug products as generic products.  It was formed as a result of the
amalgamation of Kenral Incorporated and Syncare Pharmaceutical
Incorporated.  The name-brand defendants
disposed of their beneficial ownership of AltiMed  in March 1999.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[3]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The plaintiff’s claim centres on what
it refers to as “pseudo-generic drug products”.  These products are manufactured on the same production lines and
are identical in composition to the name-brand drug products, save for being
labelled as originating from AltiMed. 
They are sold at much lower prices. 
The plaintiff claims that the name-brand defendants make these drug
products available for distribution by AltiMed under agreements that only allow
the pseudo-generic product to be sold immediately before a competing generic
product is about to enter the market, thereby capturing critical market share
and harming competition.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[4]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The plaintiff claims that the
name-brand defendants mislead consumers by</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>(a)       Marketing drug products at prices
substantially in excess of identical products available in the same pharmacies
across Canada; and</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>(b)       Failing to provide physicians,
pharmacists and consumers with material information about the source of their
products, and thereby permitting misleading representations to be made about
their products and pseudo-generic drug products such that consumers pay
premiums on name-brand products without receiving any corresponding benefit.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[5]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The plaintiff claims that this
practice violates various federal and provincial statutes.  I will deal with each in turn.  In dealing with these questions I have
applied the following principles as summarized by Moldaver J. in <i>Abdool v. Anaheim Management Ltd.</i>
(1995), 21 O.R. (3d) 453 (Div. Ct.) at 469:</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>(a)       All allegations of fact, unless patently
ridiculous or incapable of proof, must be accepted as proved;</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>(b)       The defendant, in order to succeed, must
show that it is plain and obvious beyond doubt that the plaintiffs could not
succeed;</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>(c)       The novelty of the cause of action will
not militate against the plaintiffs; and</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>(d)       The statement of claim must be read as
generously as possible, with a view to accommodating any inadequacies in the
form of the allegations due to drafting deficiencies.</span></p>

<p class=headingsubtitle><i><span
lang=EN-US>Competition Act</span></i></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[6]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Section 36(1) of the <i>Competition Act</i> provides a civil right
of action for damages caused by conduct contrary to Part VI of the Act.  The plaintiff claims that the defendants’
conduct violates ss. 52 and 54 of the Act and that this conduct caused damage
to them.  Sections 52 and 54 are in Part
VI of the Act.</span></p>

<p class=headingsubtitle><span lang=EN-US>Misleading Advertising, <i>Competition Act</i>, s. 52</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[7]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The relevant portions of s. 52 of the <i>Competition Act</i> are the following:</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>52. (1) No
person shall, for the purpose of promoting, directly or indirectly, the supply
or use of a product or for the purpose of promoting, directly or indirectly,
any business interest, by any means whatever, knowingly or recklessly make a
representation to the public that is false or misleading in a material respect.</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>(1.1) For
greater certainty, in establishing that subsection (1) was contravened, it is
not necessary to prove that any person was deceived or misled.</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>(1.2) For
greater certainty, a reference to the making of a representation, in this
section or in section 52.1, 74.01 or 74.02, includes permitting a representation
to be made.</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>(2) For the
purposes of this section, a representation that is</span></p>

<p class=headingQUOTE style='margin-left:108.0pt;text-indent:0cm;'><span
lang=EN-US>(a) expressed on an article offered or displayed for sale or its
wrapper or container,</span></p>

<p class=headingQUOTE style='margin-left:108.0pt;text-indent:0cm;'><span
lang=EN-US>(b) expressed on anything attached to, inserted in or accompanying
an article offered or displayed for sale, its wrapper or container, or anything
on which the article is mounted for display or sale,</span></p>

<p class=headingQUOTE style='margin-left:108.0pt;text-indent:0cm;'><span
lang=EN-US>(c) expressed on an in-store or other point-of-purchase display,</span></p>

<p class=headingQUOTE style='margin-left:108.0pt;text-indent:0cm;'><span
lang=EN-US>(d) made in the course of in-store, door-to-door or telephone
selling to a person as ultimate user, or</span></p>

<p class=headingQUOTE style='margin-left:108.0pt;text-indent:0cm;'><span
lang=EN-US>(e) contained in or on anything that is sold, sent, delivered,
transmitted or made available in any other manner to a member of the public,</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>is deemed to be
made to the public by and only by the person who causes the representation to
be so expressed, made or contained, subject to subsection (2.1).</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>(2.1) Where a
person referred to in subsection (2) is outside Canada, a representation
described in paragraph (2)(a), (b), (c) or (e) is, for the purposes of
subsection (1), deemed to be made to the public by the person who imports into
Canada the article, thing or display referred to in that paragraph.</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US> (3) Subject to subsection (2), a person who,
for the purpose of promoting, directly or indirectly, the supply or use of a
product or any business interest, supplies to a wholesaler, retailer or other
distributor of a product any material or thing that contains a representation
of a nature referred to in subsection (1) is deemed to have made that
representation to the public.</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US> (4) In a prosecution for a contravention of
this section, the general impression conveyed by a representation as well as
its literal meaning shall be taken into account in determining whether or not
the representation is false or misleading in a material respect.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[8]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The motions judge held that the
amended statement of claim did not plead a false or misleading representation
within the meaning of this provision. 
He read the statement of claim as pleading that the law imposed a positive
obligation on the defendants to make an “allegation” that the pseudo-generic
product was cheaper than but identical to the brand-name product.  He also held that there was no allegation
that the defendants “knowingly or recklessly” made a false or misleading
statement or that they made “any” statement. 
In the result, he held that no facts were pleaded to engage the
provisions of s. 52(1).</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[9]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>In my view, the motions judge erred in
so holding.  The appellant’s claim does
not rest solely on a theory that the respondents were under a positive obligation
to disclose that the pseudo-generic product was cheaper than but identical to
the more expensive brand-name product. 
Rather, the core of the claim that the plaintiff says amounts to a
violation of s. 52 is the positive representation that the drugs originate with
AltiMed, when in fact they originate from the name-brand defendants. There are
sufficient facts pleaded to support a finding that this representation is made
knowingly.  Further, under
s.&nbsp;52(1.2) making a representation includes permitting a representation to
be made.  The pleading, therefore,
alleges that the name-brand defendants are liable because they permitted
AltiMed to make the representation that the products originate with it.  As well, in determining whether the
representation is false, s.&nbsp;52(4) of the Act directs the court to consider
the “general impression” conveyed by the statement.  The general impression created by the statement that the drugs
originated with AltiMed is that it manufactured them; on the facts pleaded,
this is false.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[10]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The issues then are, whether the
representation about the origin of the pseudo-generic drugs is a representation
made “for the purpose of promoting, directly or indirectly, the supply or use
of a product” or alternatively “for the purpose of promoting, directly or
indirectly, any business interest” and whether the representation is false in a
“material respect”.  I will deal with
each of these issues in turn. </span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[11]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The ordinary meaning of the word
“promote” is to move forward or advance, or as was said by Darling Co. Ct. J.
in <i>R. v. Garibaldi Lifts Ltd.</i> (1977),
35 C.C.C. (2d) 190 (B.C. Co. Ct.) at 197, “enhancing or increasing the volume
of business for the company”.  The
representation that is said to be false in this claim is not of that character.  The theory expressed in the claim is that
the statement about the origin of the pseudo-generic drugs discourages
consumers from purchasing the pseudo-generics, not that it promotes their use
or supply.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[12]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>If the plaintiff were correct in its
application of this aspect of s. 52 to these facts, the effect would be to
stigmatize as illegal conduct what most people would not consider
unlawful.  It would, for example,
preclude a manufacturer from marketing food products under different brand
names for different prices without disclosing the fact on the label of the
lower-cost product that it is identical to the other.  It would, in effect, impose an obligation on the manufacturer to
label its products in a manner that ensured that the consumer was aware of the
very best bargain obtainable.  In my
view, the allegedly false representation could not reasonably be said to be
made for the purpose of promoting the supply of a product within the meaning of
s. 52(1).</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[13]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>I take a different view, however, of
whether the conduct pleaded amounts to the alternative means of committing the
offence, namely, “for the purpose of promoting, directly or indirectly, any
business interest”.  This court has held
that this phrase must be given a very wide meaning and can include any business
interest, not necessarily an interest with the persons who might be misled by
the representation.  Thus, in <i>R. v. Birchcliff Lincoln Mercury Sales Ltd.</i>
(1987), 36 C.C.C. (3d) 1 (Ont. C.A.) the accused was convicted for posting a
sign concerning the manner in which it charged for repairs.  The company posted the sign to promote its
business interests with the vehicle manufacturer, not with the public at
large.  Goodman J.A. held as follows at
p. 7:</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>It is clear from
these remarks that the summary conviction appeal court judge was of the view
that the Crown must prove not only that the respondent made a representation to
the public at large but that the representation was made for the purpose of
promoting the respondent's business interest with the public at large. In my
opinion she was wrong in thus interpreting the provisions of s. 36(1)(a) [now
s. 52(1)]. The words &quot;any business interest&quot; are not restricted in
any such manner by the provisions of s. 36(1) (a).</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[14]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>In my view, the term “any business
interest” must be the business interests of the person or persons making the
representation.  That is what is pleaded
in this case.  The appellant claims that
the brand-name manufacturers falsely represent the origin of the pseudo-generic
drugs to promote their business interests, namely to promote the sale of the
brand-name drugs.  This is exactly what
is pleaded in, for example, the following paragraphs of the amended statement
of claim:</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>14.       At a point unknown to the plaintiff, but
known to the defendants, the Name Brand Defendants decided to incorporate
subsidiary companies to market the Name Brand Defendants’ products under
generic labeling.</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>15.       This allowed the Name Brand Defendants to
continue selling name brand products at higher prices to uninformed consumers,
while selling the same product at lower prices under generic labeling.</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>16.       For example, the defendant Upjohn
incorporated the subsidiary Kenral as part of a strategy designed to
artificially maintain the price of its name brand products coming off patent
protection by introducing generic versions of the same products.  These two versions are sold at different
prices.  The name brand prices are
significantly higher and any loss in their sales are off-set by returns
received from the pseudo-generic version.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[15]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>In my view, the allegations, which
must be taken as true at this stage of the proceedings, can support a finding
that the false statement of origin was made to promote a business interest.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[16]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>It is also necessary to consider
whether the representation is false or misleading in a “material” respect.  A representation is material for the
purposes of s. 52(1) if it is so pertinent, germane or essential that it could
affect the decision to purchase.  See
for example <i>R. v. Kenitex Canada Ltd. et
al.</i> (1980), 51 C.P.R. (2d) 103 (Ont. Co. Ct.) (rev’d in part on other
grounds 59 C.P.R. (2d) 34 (C.A.), <i>sub nom</i>.
<i>R. v. Fell</i>.  The appellant has pleaded facts that, read generously, support
that allegation.  In particular, they
allege the following:</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>26.       The majority of consumers are unaware
that pseudo-generics exist and are identical to name brand products, and would
choose the lower-priced version of a prescription drug if presented with the
informed choice between two identical brands.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[17]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Finally, the plaintiff claims that it
has lost sales that it would have made throughout Canada if the name-brand
defendants, “through the instrumentality of AltiMed were not able to sell
identical products at two price points”. 
It thus claims it has suffered loss or damage giving it the right to sue
under s.&nbsp;36 of the Act.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[18]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Although I have some doubt that
Parliament intended to prohibit the type of conduct alleged in this case, and
appreciate that the causal connection between the false representation and loss
or damage to the plaintiff is weak, I cannot say that it is plain and obvious
that the plaintiff’s claim will fail given the broad wording of s. 52, and the
strict test to be applied in striking out a claim.  Accordingly, in my view, the motions judge erred in striking out
the statement of claim as it related to a breach of s. 52 of the <i>Competition Act</i>.  </span></p>

<p class=headingsubtitle><span lang=EN-US>Double ticketing: <i>Competition Act</i>, s. 54</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[19]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Section 54(1) of the <i>Competition Act</i> creates the offence of
double ticketing as follows:</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>54. (1) No
person shall supply a product at a price that exceeds the lowest of two or more
prices clearly expressed by him or on his behalf, in respect of the product in
the quantity in which it is so supplied and at the time at which it is so
supplied,</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>(a) on the
product, its wrapper or container; </span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>(b) on anything
attached to, inserted in or accompanying the product, its wrapper or container
or anything on which the product is mounted for display or sale; or</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>(c) on an
in-store or other point-of-purchase display or advertisement.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[20]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The motions judge held that s. 54 had
no application on the facts pleaded.  I
agree.  The offence in s.&nbsp;54 is
directed at the practice of selling goods at the higher of two different prices
that have been placed on the product or in anything attached to or accompanying
the product.  There is no allegation in
the amended statement of claim that the pseudo-generic drugs supplied to the
public had more than one price.  That
part of the claim was properly struck out.</span></p>

<p class=headingsubtitle><span lang=EN-US>Unlawful Interference with Economic
Relations and Conspiracy</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[21]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The motions judge held that while
allegations of unlawful conduct are made in the amended statement of claim “no
factual underpinning is pleaded” to sustain the tort of unlawful interference
with economic relations.  Similarly,
with respect to conspiracy, he held that the pleading is “devoid of facts
supporting an allegation of unlawful purpose”. 
With respect, I do not agree.  It
is open to the appellant to rely upon breach of s. 52 of the <i>Competition Act</i> as supplying the element
of unlawful means for both unlawful interference with economic interests and
conspiracy.  See <i>Westfair Foods Ltd. v. Lippens Inc. et al.</i> (1989), 64 D.L.R. (4<sup>th</sup>)
335 (Man. C.A.) at 338.  I have already
set out the factual basis for that allegation.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[22]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>With respect to conspiracy, the
motions judge also held that the elements necessary to support the claim as
required in <i>Pindoff Record Sales Ltd. v.
CBS Music Products Ltd.</i> (1989), 44 C.P.C. (2d) 308 (Ont. H.C.J.) were not
pleaded.  He did not identify the
elements that were not pleaded.  In <i>Pindoff</i>, at p. 313, Montgomery J.
adopted the following statement of the requirements of a pleading alleging
conspiracy:</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>Pleading.  The statement of claim should describe who
the several parties are and their relationship with each other.  It should allege the agreement between the
defendants to conspire, and state precisely what the purpose or what were the
objects of the alleged conspiracy, and it must then proceed to set forth, with
clarity and precision, the overt acts which are alleged to have been done by
each of the alleged conspirators in furtherance of the conspiracy; and lastly,
it must allege the injury and damage occasioned to the plaintiff thereby.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[23]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The amended statement of claim
contains all of those elements.  In my
view, the motions judge erred in striking out the claim as it related to
conspiracy.</span></p>

<p class=headingsubtitle><i><span
lang=EN-US>Business Practices Act</span></i><span lang=EN-US> and <i>Food and Drugs Act</i></span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[24]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The appellant also seeks to support
the torts of conspiracy and unlawful interference with economic relations on
the basis of alleged violations of the <i>Business
Practices Act</i>, R.S.O. 1990, c. B.18 and s. 9 of the <i>Food and Drugs Act</i>, R.S.C. 1985, c.&nbsp;C-34.  </span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[25]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The basis for the former claim turns
on the definition of “unfair practices” which includes the following:</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>2.         For the purposes of this Act, the
following shall be deemed to be unfair practices:</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>1.         A false, misleading or deceptive
consumer representation including, but without limiting the generality of the
foregoing,</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>…</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>xiii  a representation using exaggeration,
innuendo or ambiguity as to a material fact or <u>failing to state a material
fact if such use or failure deceives or tends to deceive,  </u>[Emphasis added.]</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[26]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The appellant alleges in the statement
of claim that the failure to state on the pseudo-generic drugs that they are
identical in every way to the more expensive brand-name version constitutes the
failure to state a material fact within clause (xiii).  However, this Act only applies to deceptive
“consumer” representations.  “Consumer”
is defined in s. 1 of the Act as a natural person “not … acting in the course
of carrying on business”.  As the
respondents point out, this legislation is directed primarily at transactions
involving individual consumers.  The
amended statement of claim makes it clear that the representations by the
defendants are not made to consumers but to physicians and pharmacists.  </span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[27]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The motions judge held that, “No facts
are pleaded to support an allegation that any of the defendants made the
required representation.  Facts pleaded
state the defendants sell to physicians and pharmacists, who do not fall within
the definition of consumer.”  I
agree.  That portion of the amended
statement of claim referring to the <i>Business
Practices Act</i> was properly struck out.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[28]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>With respect to the <i>Food and Drugs Act</i>, the appellant relies
upon s. 9, as follows:</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>9. (1) No person
shall label, package, treat, process, sell or advertise any drug in a manner
that is false, misleading or deceptive or is likely to create an erroneous
impression regarding its character, value, quantity, composition, merit or
safety.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[29]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The amended statement of claim may
fairly be read as alleging a violation of this section by AltiMed in that the
pseudo-generic drugs are labeled as having originated with (i.e. manufactured
by) AltiMed.  The appellant argues that
this labeling is misleading since the brand-name defendants manufacture the
drugs.  The appellant also argues that
the labeling creates an erroneous impression as to the character of the drug
because there is no disclosure that the AltiMed  drugs are identical in all respects to the brand-name drugs.</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[30]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The motions judge held as follows:</span></p>

<p class=headingQUOTE style='text-indent:0cm'><span lang=EN-US>The evil to be
prevented [by s. 9] is the purchase of something different than that which was
bargained for.  No facts were pleaded as
to the making of a false or misleading representation, or to suggest the drugs
purchased were different from the drugs intended to be purchased.”</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[31]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>In my view, the motions judge is
probably correct as to the purpose of s. 9. 
However, it is not plain and obvious that with regard to AltiMed the
allegations in the amended statement of claim do not fall within the very broad
wording of s. 9.</span></p>

<p class=headingtitle><span lang=EN-US>DISPOSITION</span></p>

<p class=headingNUMBER style='margin-left:0cm;text-indent:0cm;line-height:normal'><span
lang=EN-US>[32]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Accordingly, I would allow the appeal,
set aside the order of Jennings J., and, in its place, make an order striking
out only those allegations relating to the <i>Business
Practices Act</i> and s. 54 of the <i>Competition
Act</i>.  The appellant has achieved
substantial success on this appeal and is entitled to its costs of the appeal
and of the motions.</span></p>

<p class=MsoNormal style='margin-left:216.0pt'><span lang=EN-US>(signed) “M.
Rosenberg J.A.”</span></p>

<p class=MsoNormal style='margin-left:216.0pt'><span lang=EN-US>(signed) “I
agree R. McMurtry C.J.O.”</span></p>

<p class=MsoNormal style='margin-left:216.0pt'><span lang=EN-US>(signed) “I
agree J. W. Morden J.A.”</span></p>

<p class=headingtitle><span lang=EN-US>RELEASED: December 14, 2000 “RMc.”</span></p>

<p class=headingtitle><span lang=EN-US>&nbsp;</span></p>

</div>

</body>

</html>
